Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Xerenex Kidney Treatment: A Game Changer for Keryx Biopharmaceuticals (KERX)

Data from the United States Renal Data System revealed that almost 600 million people have ESRD, as of 2010. According to the Centers for Disease Control and Prevention, one in 10 American adults or more than 20 million have some level of chronic kidney disease. The National Kidney and Urologic Diseases Information Clearing House (NKUDIC) indicate that the most common causes of kidney failure are diabetes and high blood pressure. There are more than 25.8 million people in United States that have diabetes, based on data from the American Diabetes Association. These figures show that the number of patients in need of ESRD treatments will grow in the years ahead. Given Zenerex’s positive safety and efficacy results, it has great potential for growth once approved by government regulators.

The shares of Keryx Biopharmaceuticals surged to more than 90 percent recently. Its market value increased to $435.6 million. The company expects to file a New Drug Application (NDA) with the FDA and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for Zerenex in the second quarter this year.

The article Xerenex Kidney Treatment: A Game Changer for Keryx Biopharmaceuticals originally appeared on and is written by Marivic Cabural.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.